Prevention of Programmed Death in Hematopoietic Progenitor Cells by Hematopoietic Growth Factors

Physiology ◽  
1993 ◽  
Vol 8 (4) ◽  
pp. 170-174
Author(s):  
MJ Koury ◽  
MC Bondurant

Hematopoietic growth factors have been thought to control blood cell production by stimulating proliferation and differentiation of hematopoietic progenitor cells. However, recent studies show that these growth factors prevent programmed death in progenitor cells. A model of hematopoiesis based on prevention of this death by hematopoietic growth factors is presented.

Blood ◽  
1996 ◽  
Vol 88 (8) ◽  
pp. 2871-2877 ◽  
Author(s):  
K Takenaka ◽  
K Nagafuji ◽  
M Harada ◽  
S Mizuno ◽  
T Miyamoto ◽  
...  

Fas antigen (Fas Ag; CD95) is a cell surface molecule that can mediate apoptosis. Bcl-2 is a cytoplasmic molecule that prolongs cellular survival by inhibiting apoptosis. To investigate the role of both molecules in hematopoiesis, we evaluated the expression of Fas Ag and Bcl-2 on CD34+ hematopoietic progenitor cells expanded in vitro. CD34+ cells isolated from bone marrow were cultured in iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum, 1% bovine serum albumin, 50 ng/mL stem cell factor, 50 ng/mL interleukin-3 (IL-3), 50 ng/mL IL-6, 100 ng/mL granulocyte colony-stimulating factor, and 3 U/mL erythropoietin for 7 days. Colony-forming unit of granulocytes/macrophages (CFU-GM) and burst-forming unit of erythroids (BFU-E) were expanded 6.9-fold and 8.8-fold in number at day 5 of culture, respectively. Freshly isolated CD34+ cells did not express Fas Ag, whereas approximately half of them expressed Bcl-2. CD34+ cells cultured with hematopoietic growth factors gradually became positive for Fas Ag and rapidly lost Bcl-2 expression. Furthermore, apoptosis was induced in the cultured CD34+ population when anti-Fan antibody (IgM; 1 microgram/mL) was added, as shown by significant decrease in the number of viable cells, morphologic changes, induction of DNA fragmentation, and significant decrease in the number of clonogenic progenitor cells including CFU. GM and BFU-E. These results indicate that functional expression of Fas Ag is induced on CD34+ cells expanded in vitro in the presence of hematopoietic growth factors. Induction of Fas Ag and downregulation of Bcl-2 may be expressed as part of the differentiation program of hematopoietic cells and may be involved in the regulation of hematopoiesis.


2009 ◽  
pp. 247-252
Author(s):  
M Hofer ◽  
A Vacek ◽  
M Pospíšil ◽  
J Holá ◽  
D Štreitová ◽  
...  

Adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5’-Nmethyluronamide (IB-MECA) has been tested from the point of view of potentiating the effects of hematopoietic growth factors interleukin-3 (IL-3), stem cell factor (SCF), granulocytemacrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) on the growth of hematopoietic progenitor cells for granulocytes and macrophages (GM-CFC) in suspension of normal mouse bone marrow cells in vitro. IB-MECA alone induced no GM-CFC growth. Significant elevation of numbers of GM-CFC evoked by the combinations of IB-MECA with IL-3, SCF, or GM-CSF as compared with these growth factors alone has been noted. Combination of IB-MECA with G-CSF did not induce significantly higher numbers of GM-CFC in comparison with G-CSF alone. Joint action of three drugs, namely of IB-MECA + IL-3 + GM-CSF, produced significantly higher numbers of GM-CFC in comparison with the combinations of IB-MECA + IL-3, IB-MECA + GM-CSF, or IL-3 + GM-CSF. These results give evidence of a significant role of selective activation of adenosine A3 receptors in stimulation of the growth of granulocyte/ macrophage hematopoietic progenitor cells.


1998 ◽  
Vol 1 (3) ◽  
pp. 209-221 ◽  
Author(s):  
John Carl Panetta

Blood cell production is one of the major limiting effects of cell-cycle-specific chemotherapy. By studying the effects of the drugs on a mathematical model of hematopoiesis, a better understanding of how to prevent over-reduction of circulating blood may be investigated.In this model we will use a delay-differential equation developed by Mackey and Glass (1977) to show acceptable chemotherapeutic deses (i.e. survival of the circulating blood cells) as a function of: the period which the drugs are administered; the strength of the dose; and the delay from initiation of blood cell production to its release into the blood stream. We then make qualitative comparisons to know effects of cell-cycle-specific chemotherapy on circulating blood cell elements. Finally, we also consider how the effects of hematopoietic growth factors alter the outcome of the therapy.


1996 ◽  
Vol 38 (0) ◽  
pp. S64-S68 ◽  
Author(s):  
T. Nakahata ◽  
Xingwei Sui ◽  
Ryuhei Tanaka ◽  
Sakura Tajima ◽  
Kenji Muraoka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document